Omeros Corporation Overview
Pro stress-test →Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. The FDA approved YARTEMLEA® (narsoplimab-wuug) in December 2025 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is the first and only approved lectin pathway inhibitor.
Strategic Profile
Pro stress-test →With a U.S. launch planned for January 2026, the company is focused on ensuring rapid, reliable access to YARTEMLEA. Under a recently announced asset purchase and licensing agreement, Novo Nordisk acquired global rights to zaltenibart (formerly OMS906), a MASP-3 inhibitor in clinical development for PNH and other alternative pathway indications. The company maintains a diversified pipeline including OMS1029, OMS527 for cocaine use disorder, and immuno-oncology programs.
Competitive Landscape
Pro stress-test →Omeros operates in the specialized complement pathway disorder market with first-mover advantage in lectin pathway inhibition. Key competitors in complement-mediated disease space include Alexion (AstraZeneca), Achillion (Alexion subsidiary), and Akcea Therapeutics. The broader immunology market is competitive but TA-TMA represents an orphan indication with limited treatment options prior to YARTEMLEA's approval, reducing direct competition in the near term.
Industry Context
Omeros Corporation operates in Biopharmaceuticals - Specialty/Orphan Drugs.
Key facts
Founded: 1994 · Headquarters: Seattle, Washington